US5482930A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
Assignee: California State University System
•
Filing: 1993-06-09
•
Granted: 1996-01-09
•
Expires: 2013-06-09
Abstract
Abstract A method for treating inflammatory conditions is provided in which a peptide is administered in an amount effective to decrease inflammation, with the peptide having the sequence G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q (SEQ ID NO:1), G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q-NH2 (SEQ ID NO:2), Ac-R-R-I-R-P-K-L-NH2 (SEQ ID NO:3), or Ac-R-R-I-R-P-K-l-NH2.
Inventors
- 👤 Edward T. Wei
- 👤 Holly A. Thomas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:46
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/33; A61P; A61P29/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
55 words
An anti-inflammatory composition comprising: an amidated peptide or salt thereof having the sequence Ac-R-R-I-R-P-K-L-NH 2 (SEQ ID NO:3), or Ac-R-R-I-R-P-K-l-NH 2 in a concentration sufficient to provide about 0.1 to about 5 mg/kg patient body weight when administered by intravenous, intradermal, or subcutaneous injection to a patient, the peptide being in a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
55 words
An anti-inflammatory composition comprising: an amidated peptide or salt thereof having the sequence Ac-R-R-I-R-P-K-L-NH 2 (SEQ ID NO:3), or Ac-R-R-I-R-P-K-l-NH 2 in a concentration sufficient to provide about 0.1 to about 5 mg/kg patient body weight when administered by intravenous, intradermal, or subcutaneous injection to a patient, the peptide being in a pharmaceutically acceptable carrier.
Claim 3
Independent Claim
57 words
A method for treating a patient for an acute inflammatory condition in which vascular leakage is a factor comprising: administering to the patient an amount of a peptide, including salts thereof, in an amount effective to decrease inflammation, the peptide administered having a core sequence, the core sequence having -Arg-Arg-Ile-Arg-Pro-Lys-Leu- (SEQ ID NO:5), the peptide being non-opiate.
Claim 4
Independent Claim
57 words
A method for treating a patient for an acute inflammatory condition in which vascular leakage is a factor comprising: administering to the patient an amount of a peptide, including salts thereof, in an amount effective to decrease inflammation, the peptide administered having a core sequence, the core sequence having -Arg-Arg-Ile-Arg-Pro-Lys-Leu- (SEQ ID NO:5), the peptide being non-opiate.
Claim 5
Dependent Claim
14 words
The method as in claim 2 wherein the acute inflammatory condition is pulmonary edema.
Claim 6
Dependent Claim
18 words
The method as in claim 2 or 3 wherein the administering is by intravenous, intradermal, or subcutaneous injection.
Claim 7
Dependent Claim
32 words
The method as in claim 4 wherein the peptide is administered in combination with a pharmaceutically acceptable carrier and is optionally modified to convey resistance to enzymatic degradation or to enhance stability.
Claim 8
Dependent Claim
27 words
The method as in claim 2 wherein the administering is an injected or infused dose of between about 0.1 to about 0.5 mg/kg of patient body weight.
Claim 9
Dependent Claim
33 words
The method as in claim 2 wherein the peptide or salt thereof has the sequence G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q (SEQ ID NO:1), G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q-NH 2 (SEQ ID NO:2), Ac-R-R-I-R-P-K-L-NH 2 (SEQ ID NO:3), or Ac-R-R-I-R-P-K-l-NH 2 .
Claim 10
Independent Claim
47 words
A method for treating inflammatory conditions of tissue comprising: exposing the tissue to an amidated peptide or salt thereof having the sequence G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q (SEQ ID NO:1), G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q-NH 2 (SEQ ID NO:2), Ac-R-R-I-R-P-K-L-NH 2 (SEQ ID NO:3 ), or Ac-R-R-I-R-P-K-l-NH 2 in combination with a pharmaceutically acceptable carrier.
Claim 11
Independent Claim
47 words
A method for treating inflammatory conditions of tissue comprising: exposing the tissue to an amidated peptide or salt thereof having the sequence G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q (SEQ ID NO:1), G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q-NH 2 (SEQ ID NO:2), Ac-R-R-I-R-P-K-L-NH 2 (SEQ ID NO:3 ), or Ac-R-R-I-R-P-K-l-NH 2 in combination with a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
20 words
The method as in claim 8 wherein the tissue includes an organ prior to or during its removal for transplantation.
Claim 13
Dependent Claim
23 words
The method as in claim 8 wherein the tissue is exposed about two hours before injury and up to about three days thereafter.
References Cited (Backward Citations)
US4396606A
Cited
US4361553A
Cited
US4462941A
Cited
US4481191A
Cited
US4684624A
Cited
US5177060A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-01-08 | 1999-07-10 | 2000-01-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-01-08 | 2003-07-10 | 2004-01-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-01-08 | 2007-07-10 | 2008-01-09 | $7700.00 | Window Closed / Lapsed |